Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010–2011: a population-based test-negative case–control study

BMC Public Health

Jesús Castilla²  Esther Albeniz³  Maite Arriazu²  Fátima Irisarri²  Julio Morán³  Manuel García Cenoz²  Marcela Guevara²  Gabriel Reina¹  Víctor Martínez-Artola⁴  Iván Martínez-Baz² 

[1] Clínica Universidad de Navarra, Pamplona, Spain;CIBER Epidemiología y Salud Pública, Pamplona, Spain;Dirección de Atención Primaria, Servicio Navarro de Salud, Pamplona, Spain;Complejo Hospitalario de Navarra, Pamplona, Spain

关键词: Spain;    Case–control studies;    Influenza vaccines;    H1N1 subtype;    Influenza A virus;   

Others  :  1162488
DOI  :  10.1186/1471-2458-13-191

 received in 2012-04-05, accepted in 2013-02-28,  发布年份 2013

【 摘 要 】

Background

Some studies have evaluated vaccine effectiveness in preventing outpatient influenza while others have analysed its effectiveness in preventing hospitalizations. This study evaluates the effectiveness of the trivalent influenza vaccine in preventing outpatient illness and hospitalizations from laboratory-confirmed influenza in the 2010–2011 season.

Methods

We conducted a nested case–control study in the population covered by the general practitioner sentinel network for influenza surveillance in Navarre, Spain. Patients with influenza-like illness in hospitals and primary health care were swabbed for influenza testing. Influenza vaccination status and other covariates were obtained from health care databases. Using logistic regression, the vaccination status of laboratory-confirmed influenza cases was compared with that of test-negative controls, adjusting for age, sex, comorbidity, outpatient visits in the previous 12 months, health care setting, time between symptom onset and swabbing, period and A(H1N1)pdm09 vaccination. Effectiveness was calculated as (1-odds ratio)x100.

Results

The 303 confirmed influenza cases (88% for A(H1N1)pdm09 influenza) were compared with the 286 influenza test-negative controls. The percentage of persons vaccinated against influenza was 4.3% and 15.7%, respectively (p<0.001). The adjusted estimate of effectiveness was 67% (95% CI: 24%, 86%) for all patients and 64% (95% CI: 8%, 86%) in those with an indication for vaccination (persons age 60 or older or with major chronic conditions). Having received both the 2010–2011 seasonal influenza vaccine and the 2009–2010 pandemic influenza vaccine provided 87% protection (95% CI: 30%, 98%) as compared to those not vaccinated.

Conclusion

The 2010–2011 seasonal influenza vaccine had a moderate protective effect in preventing laboratory-confirmed influenza.

【 授权许可】

   
2013 Martínez-Baz et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Glezen WP: Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982, 4:25-44.
• [2]Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K: Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
• [3]Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E: Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007, 357:1373-1381.
• [4]Osterholm MT, Kelley NS, Sommer A, Belongia EA: Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:36-44.
• [5]Orenstein WA, Bernier RH, Hinman AR: Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev 1988, 10:212-240.
• [6]Valenciano M, Kissling E, Ciancio BC, Moren A: Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioners networks. Vaccine 2010, 28:7381-7388.
• [7]Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS: Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006, 35:337-344.
• [8]Jefferson T, Rivetti A, Rudin M, Pietrantonj A, Demicheli V: Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005, 366:1165-1174.
• [9]Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, Orenstein WA: Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol 2007, 36:623-631.
• [10]Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, Stefanoff P, Nunes B, Pitigoi D, Larrauri A, Daviaud I, Horvath JK, O'Donnell J, Seyler T, Paradowska-Stankiewicz IA, Pechirra P, Ivanciuc AE, Jiménez-Jorge S, Savulescu C, Ciancio BC, Moren A: I-MOVE Multi-Centre Case Control Study 2010–11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe. PLoS One 2011, 6(11):e27622.
• [11]Pebody R, Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, Thomas D, Sebastianpillai P, Ellis J, Carman W, Wreghitt T, Zambon M, Watson J: Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Euro Surveill 2011, 16(6):pii=19791.
• [12]Fielding JE, Grant KA, Garcia K, Kelly HA: Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerg Infect Dis 2011, 17:1181-1187.
• [13]Puig-Barberà J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD, Pérez Vilar S, Silvestre-Silvestre E, Calvo-Mas C, Safont-Adsuara L, Ruiz-García M: Surveillance and Vaccine Evaluation Group during the autumn 2009 H1N1 pandemic wave in Castellón, Spain: Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test negative, hospital-based, case–control study. Vaccine 2010, 28:7460-7467.
• [14]Castilla J, Martínez-Artola V, Salcedo E, Martínez-Baz I, Cenoz MG, Guevara M, Alvarez N, Irisarri F, Morán J, Barricarte A: Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010–2011: cohort and case–control study. Vaccine 2012, 30:195-200.
• [15]World Health Organization: Recommended virus for influenza vaccines for use in the 2010–2011 northern hemisphere influenza. Wkly Epidemiol Rec 2010, 85:81-92.
• [16]World Health Organization: Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development. Geneva: WHO; 2009. http://www.who.int/csr/resources/publications/swineflu/ivr153_20090608_en.pdf webcite
• [17]Instituto de Salud Pública de Navarra: Protocolo de vacunación antigripal 2010–2011. Boletín Informativo nº 59. 2010. http://www.navarra.es/NR/rdonlyres/AECCD760-AB2A-4841-818A-FA53478FD6DC/165169/BOL59INTCampanaGripe.pdf webcite
• [18]Aguilar I, Reyes M, Martinez-Baz I, Guevara M, Albeniz E, Belza M, Castilla J: Use of the vaccination register to evaluate influenza vaccine coverage in seniors in the 2010/11 influenza season, Navarre, Spain. Euro Surveill 2012, 17(17):pii: 20154.
• [19]Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I: Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
• [20]Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, Zhang XF, Pan HX, Meng FY, Hu YM, Liu WD, Li CG, Li W, Zhang X, Hu JM, Peng WB, Yang BP, Xi P, Wang HQ, Zheng JS: A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
• [21]Plennevaux E, Sheldon E, Blatter M, Reeves-Haché MK, Denis M: Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
• [22]Groenwold RH, Hoes AW, Nichol KL, Hak E: Quantifying the potential role of unmeasured confounders: the example of influenza vaccination. Int J Epidemiol 2008, 37:1422-1429.